MedTrace Logo

А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

NCT04524975 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2020-08-24

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding pilot study to assess the efficacy and safety of CD-008-0045 in patients with Generalized Anxiety Disorder (GAD). Each patient will participate in the study for the period of approximately 10 weeks: Screening and Run-in period: 1 week; Study Treatment period: 8 weeks; Follow-up period: 1 week.

Conditions

  • Anxiety Disorder Generalized

Interventions

DRUG

CD-008-0045

CD-008-0045 20 mg capsules

DRUG

Placebo

Placebo capsules

Sponsors & Collaborators

  • ChemRar Research and Development Institute, LLC

    lead INDUSTRY

Principal Investigators

  • Margarita A Morozova, MD,PhD,Prof · "Research Center for Mental Health" Scientific Institution

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-02
Primary Completion
2019-08-20
Completion
2019-11-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524975 on ClinicalTrials.gov